| __timestamp | Arrowhead Pharmaceuticals, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 35942000 |
| Thursday, January 1, 2015 | 34718089 | 40028000 |
| Friday, January 1, 2016 | 40998209 | 45853000 |
| Sunday, January 1, 2017 | 32022880 | 53816000 |
| Monday, January 1, 2018 | 19110051 | 60804000 |
| Tuesday, January 1, 2019 | 26556257 | 77252000 |
| Wednesday, January 1, 2020 | 52275890 | 45736000 |
| Friday, January 1, 2021 | 80981000 | 50323000 |
| Saturday, January 1, 2022 | 124431000 | 143526000 |
| Sunday, January 1, 2023 | 90932000 | 149182000 |
| Monday, January 1, 2024 | 98761000 | 154335000 |
Data in motion
In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Halozyme's SG&A expenses have shown a steady increase, peaking in 2023 with a 315% rise from 2014. Arrowhead, on the other hand, experienced a more volatile trajectory, with a notable spike in 2022, marking a 410% increase from its 2014 figures. This fluctuation highlights the dynamic nature of the biotech industry, where strategic investments in administration and sales can significantly impact a company's financial landscape. Interestingly, the data for 2024 is incomplete, suggesting a potential shift in Arrowhead's financial strategy. As these companies continue to innovate, their operational costs will remain a critical factor in their success.
Sanofi and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
Rhythm Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.